Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accent Microcell's Days Sales Outstanding for the
six
months ended in Mar. 2025 was 81.86.
Accent Microcell's Days Inventory for the
six
months ended in Mar. 2025 was 74.
Accent Microcell's Days Payable for the
six
months ended in Mar. 2025 was 41.9.
Therefore, Accent Microcell's Cash Conversion Cycle (CCC) for the
six
months ended in Mar. 2025 was 113.96.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Accent Microcell Cash Conversion Cycle Related Terms
Accent Microcell Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Accent Microcell's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accent Microcell Cash Conversion Cycle Chart
Accent Microcell Annual Data
Trend
Mar21
Mar22
Mar23
Mar24
Mar25
Cash Conversion Cycle
86.25
68.41
69.15
88.56
113.96
Accent Microcell Semi-Annual Data
Mar21
Mar22
Mar23
Mar24
Mar25
Cash Conversion Cycle
86.25
68.41
69.15
88.56
113.96
NSE:ACCENTMIC vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accent Microcell's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accent Microcell Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accent Microcell's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Accent Microcell's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Accent Microcell's Cash Conversion Cycle for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accent Microcell (NSE:ACCENTMIC) has a Cash Conversion Cycle of 113.96 as of Mar. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Accent Microcell and its competitors.
Is Accent Microcell's Cash Conversion Cycle too high?
Accent Microcell's current Cash Conversion Cycle is 113.96. The Drug Manufacturers industry median Cash Conversion Cycle is 145.92. Accent Microcell's value of 113.96 is 21.9% below this industry median. Overall, Accent Microcell has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Accent Microcell's Cash Conversion Cycle compare to ZTS and UTHR?
Accent Microcell's Cash Conversion Cycle of 113.96 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.92. Accent Microcell's value of 113.96 is 21.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.92, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accent Microcell's current Cash Conversion Cycle of 113.96 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Accent Microcell and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accent Microcell's current Cash Conversion Cycle is 113.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accent Microcell stock overvalued right now?
Accent Microcell (NSE:ACCENTMIC) has a current Cash Conversion Cycle of 113.96. The current Cash Conversion Cycle is 113.96 and 21.9% below the Drug Manufacturers industry median of 145.92. Accent Microcell's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Accent Microcell (NSE:ACCENTMIC), the current Cash Conversion Cycle is 113.96 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accent Microcell Ltd is engaged in the manufacturing business of pharmaceutical excipients including products like Microcrystalline Cellulose which is a term for refined wood pulp and is used as a texturizer, an anti-caking agent, a fat substitute, an emulsifier, an extender, and a bulking agent in food production; Croscarmellose Sodium used as a super disintegrant in pharmaceutical formulations; Magnesium Stearate; Cellulose Powder, and others. Its business segments are segregated based on the location of its manufacturing facilities and include Dahej (SEZ Unit), Pirana, Unit III, and Inter Unit Sales. Geographically, a majority of the company's revenue is derived through the export of its products to various countries.
19GF Score
Get the complete analysis for NSE:ACCENTMIC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCENTMIC has been successfully added to your 
